

Nemludio (nemolizumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:		FIRST NAME:
PHONE NUMBER:		DATE OF BIRTH:
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

☐ MALE ☐ FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](https://www.primetherapeutics.com/nopp)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

Nemludio (nemolizumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?

☐ YES (if yes, complete below) ☐ NO

MEDICATION/THERAPY
(SPECIFY DRUG NAME AND
DOSAGE):

DURATION OF THERAPY
(SPECIFY DATES):

**RESPONSE/REASON FOR
FAILURE/ALLERGY:**

2. LIST DIAGNOSES:

ICD-10:

☐ Moderate to severe atopic dermatitis

☐ Prurigo Nodulatis

☐ Other diagnosis: _____ ICD-10 Code(s):

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Will the patient be using the drug as a part of the clinical trial? ☐ Yes ☐ No

Initial:

Is the medication being prescribed by one of the following or in consultation with one of the following: ? ☐ Yes ☐ No

☐ Allergist

☐ Immunologist

☐ Dermatologist

Will Nemludio (nemolizumab) be used in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors)? ☐ Yes ☐ No

Will Nemludio (nemolizumab) be used in combo w Cibinqo (abrocitinib), Olumiant (baracitinib), RinvoqER (upadacitinib), Opzelura (ruxolitinib), or Adbry (tralokinumab), Dupixent (dupilumab) or Ebglyss (lebrikizumab)? ☐ Yes ☐ No

Has the patient tried and failed a 3-month trial of Dupixent (Please submit documentation)?

☐ Yes ☐ No

For diagnosis of Atopic Dermatitis, answer the following:

Has the patient had the diagnosis of atopic dermatitis for at least 12 months? ☐ Yes ☐ No
Please submit documentation.

Does the patient have atopic dermatitis on at least 10% or more of their body surface area?

☐ Yes ☐ No Please submit documentation.

Has the patient tried at least two different topical steroids? ☐ Yes ☐ No

Please submit documentation.

Nemluvio (nemolizumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND one topical calcineurin inhibitor (tacrolimus or pimecrolimus)? ☐ Yes ☐ No
Please submit documentation.

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Eucrisa(crisaborole)? ☐ Yes ☐ No Please submit documentation.

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Zoryve(roflumilast)? ☐ Yes ☐ No Please submit documentation.

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Vtama(tapinarof)? ☐ Yes ☐ No Please submit documentation.

For a diagnosis of Prurigo Nodularis, please answer the following:

Has patient had chronic pruritus lasting ≥ 6 weeks? ☐ Yes ☐ No Please submit documentation.

Does patient have history and/or signs of repeated scratching, picking, or rubbing (eg, excoriations and scars)? ☐ Yes ☐ No Please submit documentation.

Does patient have presence of multiple pruriginous lesions, including firm nodules? ☐ Yes ☐ No
Please submit documentation.

Has the patient tried at least 2 different medium-to-super-potent topical steroids? ☐ Yes ☐ No
Please submit documentation.

Has the patient tried at least one medium-to-super-potent topical steroid AND one topical calcineurin inhibitor (tacrolimus or pimecrolimus)? ☐ Yes ☐ No Please submit documentation.

Has the patient tried oral psoralen in combination with phototherapy AND at least one medium-to-super-potent topical steroid? ☐ Yes ☐ No Please submit documentation.

Has patient tried excimer laser AND at least one medium-to-super-potent topical steroid? ☐ Yes ☐ No Please submit documentation.

Has patient tried cryotherapy AND intralesional steroids? ☐ Yes ☐ No Please submit documentation.

Nemluvio (nemolizumab)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Has patient tried at least one oral DMARD such as methotrexate or cyclosporine? ☐ Yes ☐ No
Please submit documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Renewal Request:

Does the patient continue to have positive clinical response with continued use of Nemluvio (nemolizumab)? ☐ Yes ☐ No Please submit documentation.

Is the medication being prescribed by one of the following or in consultation with one of the following: ? ☐ Yes ☐ No

- ☐ Allergist
- ☐ Immunologist
- ☐ Dermatologist

Will Nemluvio (nemolizumab) be used in combo w Cibinqo (abrocitinib), Olumiant (baracitinib), RinvoqER (upadacitinib), Opzelura (ruxolitinib), or Adbry (tralokinumab), Dupixent (dupilumab) or Ebglyss (lebrikizumab)? ☐ Yes ☐ No

Will Nemluvio (nemolizumab) be used in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL-4 inhibitors)? ☐ Yes ☐ No

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Nemludio (nemolizumab)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909